检索结果-南通市图书馆

Regulation of AMPK activation by extracellular matrix stiffness in pancreatic cancer

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Genes & Diseases 2024年第3期11卷 338-350页

作者： Xin Xu Yuan Fang Somaira Nowsheen Ye-Xiong Li Zhenkun Lou Min Deng State Key Laboratory of Molecular Oncology and department of Radiation Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100021China department of General Surgery Shanghai General HospitalShanghai Jiaotong University School of MedicineShanghai 200080China department of General Surgery Zhongshan HospitalFudan UniversityShanghai 200032China department of dermatology University of California San DiegoSan DiegoCA 92093USA department of Oncology Mayo ClinicRochesterMN 55905USA

The adenosine monophosphate(AMP)-activated protein kinase(AMPK)sits at a cen-tral node in the regulation of energy metabolism and tumor *** is best known to sense high cellular ADP or AMP levels,which indicate the depletion of energy *** studies have shown that the low expression of phosphorylated AMPK is associated with a poor prognosis of pancreatic *** this study,we report that AMPK is also highly sensitive to extracellular matrix(ECM)*** found that AMPK is activated in cells when cultured under low ECM stiffness conditions and is functionally required for the metabolic switch induced by ECM *** regulation of AMPK requires the Hippo kinases but not LKB1/*** kinases directly phosphorylate AMPKa at Thr172 to activate AMPK at low ECM ***,we found AMPK activity is inhibited in patients with pancreatic ductal adenocarcinoma(PDAC)with high ECM stiffness and is associated with a poor survival *** activation of Hippo kinases by ROCK inhibitor Y-27632 in combination with the mitochondrial inhibitor metformin synergistically activates AMPK and dramatically inhibits PDAC ***,these findings establish a novel model for AMPK regulation by the mechanical properties of ECMs and provide a rationale for simultaneously targeting the ECM stiffness-Hippo kinases-AMPK signaling and low glucose-LKB1-AMPK signaling pathways as an effective therapeutic strategy against PDAC.

关键词： AMPKactivity Cellularmetabolic switch ECM stiffness Hippokinase signaling Pancreaticductal adenocarcinoma

Tildrakizumab for moderate-to-severe plaque psoriasis in Chinese patients:A 12-week randomized placebo-controlled phase III trial with long-term extension

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Chinese Medical Journal 2024年第10期137卷 1190-1198页

作者： Chen Yu Songmei Geng Bin Yang Yunhua Deng Fuqiu Li Xiaojing Kang Mingye Bi Furen Zhang Yi Zhao Weili Pan Zhongwei Tian Jinhua Xu Zhenghua Zhang Nan Yu Xinsuo Duan Shuping Guo Qing Sun Weiquan Li Juan Tao Zhijun Liu Yuanyuan Yin Gang Wang department of dermatology Xijing HospitalThe Fourth Military Medical UniversityXi’anShaanxi 710032China department of dermatology The Second Affiliated Hospital of Xi’an Jiaotong UniversityXi’anShaanxi 710004China department of dermatology Dermatology Hospital of Southern Medical UniversityGuangzhouGuangdong 510091China department of dermatology Tongji HospitalHuazhong University of Science and TechnologyWuhanHubei 430030China department of dermatology The Second Hospital of Jilin UniversityChangchunJilin 130041China department of dermatology People’s Hospital of Xinjiang Uygur Autonomous RegionUrumqiXinjiang 830001China department of dermatology Wuxi People’s Hospital of Wuxi CityWuxiJiangsu 214023China department of dermatology Shandong Provincial Hospital for Skin Diseases&Shandong Provincial Institute of Dermatology and VenereologyShandong First Medical University&Shandong Academy of Medical SciencesJinanShandong 250022China department of dermatology Beijing Tsinghua Changgung HospitalBeijing 102218China department of dermatology Zhejiang Provincial People’s HospitalHangzhouZhejiang 310014China department of dermatology The First Affiliated Hospital of Xinxiang Medical CollegeXinxiangHenan 453100China department of dermatology Huashan Hospital Affiliated to Fudan UniversityShanghai 200040China department of dermatology General Hospital of Ningxia Medical UniversityYinchuanNingxia 750000China department of dermatology Affiliated Hospital of Chengde Medical UniversityChengdeHebei 067000China department of dermatology The First Hospital of Shanxi Medical UniversityTaiyuanShanxi 030001China department of dermatology Qilu Hospital of Shandong UniversityJinanShandong 250012China department of dermatology Yuebei People’s HospitalShaoguanGuangdong 512026China department of dermatology Union Hospital Tongji Medical Collage Huazhong University of Science and TechnologyWuhanHubei 430022China department of dermatology and Venereal Diseases The First Affiliated Hospit

Background:There is a need for effective and safe therapies for psoriasis that provide sustained *** aim of this study was to assess the efficacy and safety of tildrakizumab,an anti-interleukin-23p19 monoclonal antibody,for treating moderate-to-severe plaque psoriasis in Chinese ***:In this multi-center,double-blind,phase III trial,patients with moderate-to-severe plaque psoriasis were enrolled and randomly assigned(1:1)to receive subcutaneous tildrakizumab 100 mg or placebo at weeks 0 and *** initially assigned to placebo were switched to receive tildrakizumab at weeks 12,16,and every 12 weeks *** in the tildrakizumab group continued with tildrakizumab at week 16,and every 12 weeks until week *** primary endpoint was the Psoriasis Area and Severity Index(PASI 75)response rate at week ***:At week 12,tildrakizumab demonstrated significantly higher PASI 75 response rates(66.4%[73/110]vs.12.7%[14/110];difference,51.4%[95%confidence interval(CI),40.72,62.13];P<0.001)and Physician’s Global Assessment(60.9%[67/110]vs.10.0%[11/110];difference,49.1%[95%CI,38.64,59.62];P<0.001)compared to *** 75 response continued to improve over time in both tildrakizumab and placebo-switching to tildrakizumab groups,reaching maximal efficacy after 28 weeks(86.8%[92/106]vs.82.4%[89/108])and maintained up to 52 weeks(91.3%[95/104]vs.87.4%[90/103]).Most treatment-emergent adverse events were mild and not related to ***:Tildrakizumab demonstrated durable efficacy through week 52 and was well tolerated in Chinese patients with moderate-to-severe plaque *** registration:***,NCT05108766.

关键词： Tildrakizumab Interleukin 23 Plaque psoriasis Chinese Randomized controlled trial

Efficacy and safety of CM310 in moderate-to-severe atopic dermatitis:A multicenter,randomized,double-blind,placebo-controlled phase 2b trial

在线全文

学校读者我要写书评

暂无评论

Chinese Medical Journal 2024年第2期137卷 200-208页

作者： Yan Zhao Jianzhong Zhang Bin Yang Jingyi Li Yangfeng Ding Liming Wu Litao Zhang Jinyan Wang Xiaohong Zhu Furen Zhang Xiaohua Tao Yumei Li Chunlei Zhang Linfeng Li Jianyun Lu Qingchun Diao Qianjin Lu Xiaoyong Man Fuqiu Li Xiujuan Xia Hao Cheng Yingmin Jia Guoqing Zhao Jinchun Yan Bo Chen department of dermatology Peking University People’s HospitalBeijing 100044China department of dermatology Dermatology HospitalSouthern Medical UniversityGuangzhouGuangdong 510091China department of dermatology West China HospitalSichuan UniversityChengduSichuan 610041China department of dermatology Shanghai Skin Disease HospitalInstitute of PsoriasisTongji University School of MedicineShanghai 200443China department of dermatology Affiliated Hangzhou First People’s HospitalZhejiang University School of MedicineHangzhouZhejiang 310006China department of dermatology Tianjin Academy of Traditional Chinese Medicine Affiliated HospitalTianjin 300120China department of dermatology Ningbo No.2 HospitalNingboZhejiang 315010China department of dermatology The Wuxi Second Affiliated Hospital of Nanjing Medical UniversityWuxiJiangsu 214002China Shandong Provincial Hospital for Skin Diseases&Shandong Provincial Institute of dermatology and Veneorology Shandong First Medical University&Shandong Academy of Medical SciencesJinanShandong 250022China center for Plastic&Reconstructive Surgery Department of DermatologyZhejiang Provincial People’s Hospital(Affiliated People’s HospitalHangzhou Medical College)HangzhouZhejiang 310014China department of dermatology Affiliated Hospital of Jiangsu UniversityZhenjiangJiangsu 212001China department of dermatology Peking University Third HospitalBeijing 100191China department of dermatology Beijing Friendship HospitalCapital Medical UniversityBeijing 100050China department of dermatology The Third Xiangya Hospital of Central South UniversityChangshaHunan 410013China department of dermatology Chongqing Traditional Chinese Medicine HospitalChongqing 400011China Hunan Key Laboratory of Medical Epigenomics Department of DermatologyThe Second Xiangya Hospital of Central South UniversityChangshaHunan 410011China department of dermatology The Second Affiliated HospitalZhejiang University School of MedicineHangzhouZhejiang 310009China Departme

Background:Atopic dermatitis(AD)affects approximately 10%of adults ***310 is a humanized monoclonal antibody targeting interleukin-4 receptor alpha that blocks interleukin-4 and interleukin-13 *** trial aimed to evaluate the efficacy and safety of CM310 in Chinese adults with moderate-to-severe ***:This multicenter,randomized,double-blind,placebo-controlled,phase 2b trial was conducted in 21 medical institutions in China from February to November *** 120 eligible patients were enrolled and randomized(1:1:1)to receive subcutaneous injections of 300 mg CM310,150 mg CM310,or placebo every 2 weeks for 16 weeks,followed by an 8-week follow-up *** primary endpoint was the proportion of patients achieving≥75%improvement in the Eczema Area and Severity Index(EASI-75)score from baseline at week *** and pharmacodynamics were also ***:At week 16,the proportion of EASI-75 responders from baseline was significantly higher in the CM310 groups(70%[28/40]for high-dose and 65%[26/40]for low-dose)than that in the placebo group(20%[8/40]).The differences in EASI-75 response rate were 50%(high ***,95%CI 31%-69%)and 45%(low ***,95%CI 26%-64%),with both P valuesdermatology Life Quality Index compared with ***310 treatment reduced levels of thymus and activation-regulated chemokine,total immunoglobulin E,lactate dehydrogenase,and blood *** incidence of treatment-emergent adverse events(TEAEs)was similar among all three groups,with the most common TEAEs reported being upper respiratory tract infection,atopic dermatitis,hyperlipidemia,and *** severe adverse events were deemed to be attributed to ***:CM310 at 150 mg and 300 mg every 2 weeks demonstrated significant efficacy and was well-tol

关键词： CM310 Moderate-to-severe atopic dermatitis Interleukin-4 receptor alpha Adults

cancer stem cells: advances in knowledge and implications for cancer therapy

在线全文

学校读者我要写书评

暂无评论

Signal Transduction and Targeted Therapy 2024年第8期9卷 3242-3304页

作者： Xianjing Chu Wentao Tian Jiaoyang Ning Gang Xiao Yunqi Zhou Ziqi Wang Zhuofan Zhai Guilong Tanzhu Jie Yang Rongrong Zhou department of Oncology Xiangya HospitalCentral South UniversityChangsha 410008China department of dermatology Xiangya HospitalCentral South UniversityChangsha 410008China xiangya Lung cancer center Xiangya HospitalCentral South UniversityChangsha 410008China National Clinical Research center for Geriatric Disorders Xiangya HospitalCentral South UniversityChangshaHunan Province 410008China

cancer stem cells(CSCs),a small subset of cells in tumors that are characterized by self-renewal and continuous proliferation,lead to tumorigenesis,metastasis,and maintain tumor *** continues to be a significant global disease *** the past,surgery,radiotherapy,and chemotherapy were the main cancer *** technology of cancer treatments continues to develop and advance,and the emergence of targeted therapy,and immunotherapy provides more options for patients to a certain ***,the limitations of efficacy and treatment resistance are still *** review begins with a brief introduction of the historical discoveries,original hypotheses,and pathways that regulate CSCs,such as WNT/β-Catenin,hedgehog,Notch,NFkB,JAK/STAT,TGF-β,PI3K/AKT,PPAR pathway,and their *** focus on the role of CSCs in various therapeutic outcomes and resistance,including how the treatments affect the content of CSCs and the alteration of related molecules,CSCs-mediated therapeutic resistance,and the clinical value of targeting CSCs in patients with refractory,progressed or advanced *** summary,CSCs affect therapeutic efficacy,and the treatment method of targeting CSCs is stll difficult to *** regulatory mechanisms and targeting biomarkers of CSCs is currently the mainstream idea.

关键词： cancer maintain knowledge

Molecular and therapeutic landscape of ferroptosis in skin diseases

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

中华医学杂志(英文版) 2024年第15期137卷 1777-1789页

作者： Le Jiayuan Meng Yu Wang Ying Li Daishi Zeng Furong Xiong Yixiao Chen Xiang Deng Guangtong department of dermatology Xiangya Hospital Central South University Changsha Hunan China National Engineering Research center of Personalized Diagnostic and Therapeutic Technology Changsha Hunan China Furong Laboratory Changsha Hunan China Hunan Key Laboratory of Skin cancer and Psoriasis Hunan Engineering Research Center of Skin Health and Disease Xiangya Hospital Central South University Changsha Hunan China National Clinical Research center for Geriatric Disorders Xiangya Hospital Changsha Hunan China department of Oncology Xiangya Hospital Central South University Changsha Hunan China department of dermatology Tongji Hospital Huazhong University of Science and Technology Wuhan Hubei China

Regulated cell death (RCD) is a critical physiological process essential in maintaining skin homeostasis. Among the various forms of RCD, ferroptosis stands out due to its distinct features of iron accumulation, lipid peroxidation, and involvement of various inhibitory antioxidant systems. In recent years, an expanding body of research has solidly linked ferroptosis to the emergence of skin disorders. Therefore, understanding the mechanisms underlying ferroptosis in skin diseases is crucial for advancing therapy and prevention strategies. This review commences with a succinct elucidation of the mechanisms that underpin ferroptosis, embarks on a thorough exploration of ferroptosis’s role across a spectrum of skin conditions, encompassing melanoma, psoriasis, systemic lupus erythematosus (SLE), vitiligo, and dermatological ailments precipitated by ultraviolet (UV) exposure, and scrutinizes the potential therapeutic benefits of pharmacological interventions aimed at modulating ferroptosis for the amelioration of skin diseases.

关键词： Ferroptosis Skin diseases Regulated cell death Homeostasis Melanoma Psoriasis Systemic lupus erythematosus Vitiligo

Current status of cognition and skin care behavior in adolescent patients with acne:A survey in China

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

Chinese Medical Journal 2024年第4期137卷 476-477页

作者： Jing Tian Hong Shu Qiufang Qian Zhong Shen Chunyu Zhao Li Song Ping Li Xiuping Han Hua Qian Jinping Chen Hua Wang Lin Ma Yuan Liang department of dermatology Beijing Children’s HospitalCapital Medical UniversityNational Center for Children’s HealthBeijing 100045China department of dermatology Kunming Children’s HospitalKunmingYunnan 650034China department of dermatology Children’s Hospital of ShanghaiChildren’s Hospital Affiliated to Shanghai Jiao Tong University School of MedicineShanghai 200127China Loreal China Co. LtdShanghai 200040China department of dermatology Henan Children’s HospitalChildren’s Hospital Affiliated to Zhengzhou UniversityZhengzhou Hospital Beijing Children’s HospitalZhengzhou Children’s HospitalZhengzhouHenan 450052China department of dermatology Shenzhen Children’s HospitalShenzhenGuangdong 518026China department of dermatology Shengjing Hospital of China Medical UniversityShenyangLiaoning 110004China department of dermatology Children’s Hospital of Soochow UniversitySuzhouJiangsu 215025China department of dermatology Guangzhou Women and Children's Medical CenterGuangzhouGuangdong 510623China department of dermatology Children’s Hospital of Chongqing Medical UniversityChongqing 400014China

To the Editor:Acne vulgaris(AV)is a common inflammatory skin ***-based epidemiological studies have reported associations between dietary habits,lifestyle factors,family history,and the occurrence and development of acne.^([1–4])This study investigated the skincare behavior and cognition of patients with AV regarding predisposing factors using a designed electronic questionnaire.

关键词： patients dietary behavior

Comorbidities of prurigo nodularis in Chinese patients:A multicenter retrospective study

在线全文

学校读者我要写书评

暂无评论

Chinese Medical Journal 2024年第11期137卷 1360-1362页

作者： Mengting Yin Weilong Zhong Keren Zhou Xia Dou department of dermatology Peking University Shenzhen HospitalShenzhenGuangdong 518036China National Clinical Research center for Skin and Immune Diseases Beijing 100034China

Prurigo nodularis(PN),as a subtype of chronic prurigo(CPG),is characterized by nodular lesions and severe pruritus,which signicantly affect patients’quality of life.[1]It has been observed that patients with PN often have comorbidities,including physical and mental diseases.[2]However,information on comorbidities in Chinese PN patients is *** study aims toll this gap by using a representative patient population to provide comprehensive data on comorbidities in Chinese patients with PN.

关键词： patients morbid lesions

Two hits are better than one:rational dual strategy efficiently fights neuroblastoma

在线全文

学校读者我要写书评

暂无评论

Signal Transduction and Targeted Therapy 2024年第5期9卷 1802-1804页

作者： Jacques Zimmer Camille Rolin Markus Ollert department of Infection and Immunity Luxembourg Institute of HealthEsch-sur-AlzetteLuxembourg University of Luxembourg Esch-sur-AlzetteLuxembourg department of dermatology and Allergy center Odense Research Center for Anaphylaxis(ORCA)University of Southern DenmarkOdenseDenmark

The recently published landmark paper by Bergaggio et *** Roberto Chiarle’s group in cancer Cell1 investigates an elegant double-hit strategy to improve anti-cancer *** important approach demonstrates in a preclinical model that chimeric antigen receptor(CAR)-T cell treatment can be rendered more efficient by increasing the cell surface expression of the CAR target structure via a small molecule.

关键词： neuroblastoma cancer

Chinese expert consensus on the diagnosis and treatment of balanoposthitis

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Chinese Medical Journal 2024年第13期137卷 1519-1521页

作者： Li Zhang Amer A.A.Abdulrahman Hao Guo Jia’an Zhang Xinghua Gao Weihua Pan Gang Wang Jinhua Xu Yuling Shi Liuqing Chen Hongxiang Chen Songmei Geng Yuping Ran Hongwei Wang Xiaoyong Man Jianmin Chang Furen Zhang Litao Zhang Guangwen Yin Jianzhong Zhang Wei Lai Zhibin Niu Hongkun Jiang Haibo Liu Yaolong Chen Jianjian Wang department of dermatology The First Hospital of China Medical UniversityShenyangLiaoning 110001China Key Laboratory of Immunodermatology Ministry of Education and NHCNational Joint Engineering Research Center for Theranostics of Immunological Skin DiseasesShenyangLiaoning 110001China department of dermatology Chinese Academy of Medical Science and Peking Union Medical CollegeNanjingJiangsu 210042China department of dermatology Second Affiliated Hospital of Naval Medical UniversityShanghai 200003China department of dermatology Xijing HospitalFourth Military Medical UniversityXi’anShaanxi 710032China department of dermatology Huashan HospitalFudan UniversityShanghai 200040China department of dermatology Shanghai Skin Disease HospitalTongji University School of MedicineShanghai 200443China department of dermatology Wuhan No.1 HospitalWuhanHubei 430022China department of dermatology Huazhong University of Science and Technology Union Shenzhen HospitalShenzhenGuangdong 518052China department of dermatology Second Affiliated Hospital of Xi’an Jiaotong UniversityXi’anShaanxi 710004China department of Dermatovenereology West China HospitalSichuan UniversityChengduSichuan 610041China department of dermatology Huadong HospitalFudan UniversityShanghai 200040China department of dermatology Second Affiliated HospitalZhejiang University School of MedicineHangzhouZhejiang 310009China department of dermatology Beijing HospitalBeijing 100730China Shandong Provincial Hospital for Skin Diseases&Shandong Provincial Institute of dermatology and Venereology Shandong First Medical University&Shandong Academy of Medical SciencesJinanShandong 250061China department of dermatology Tianjin Academy of Traditional Chinese Medicine Affiliated HospitalTianjin 300120China department of dermatology The First Affiliated Hospital of Zhengzhou UniversityZhengzhouHenan 450052China department of dermatology Peking University People’s HospitalBeijing 100044 China department of dermatology Third Affi

Balanoposthitis(BP),a common male genitalia inflammation,is managed by clinicians from different specialties,including urology,pediatrics,dermatology,and *** to this diverse array of clinicians involved,there exists a lack of consistent,evidence-based recommendations for *** development of the consensus engaged 19 representative hospitals and it adhered to rigorous protocols,encompassing international registration(IPGRP-2021CN003)and the application of evidence grading criteria and recommendation standards[Appendix S1,Supplementary File,http://***/CM9/C42].Over the period from December 2020 to October 2022,consensus on 12 clinical issues was reached through comprehensive evidence searches and two iterations of Delphi surveys[Supplementary File,http://***/CM9/C42].

关键词： Delphi diagnosis rigorous